↓ Skip to main content

Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis

Overview of attention for article published in Annals of Surgical Oncology, August 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (51st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
28 Mendeley
Title
Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis
Published in
Annals of Surgical Oncology, August 2015
DOI 10.1245/s10434-015-4779-6
Pubmed ID
Authors

C. Cabula, L. G. Campana, G. Grilz, S. Galuppo, R. Bussone, L. De Meo, A. Bonadies, P. Curatolo, M. De Laurentiis, M. Renne, S. Valpione, T. Fabrizio, N. Solari, M. Guida, A. Santoriello, M. D’Aiuto, R. Agresti

Abstract

The management of breast cancer (BC) skin metastases represents a therapeutic challenge. Electrochemotherapy (ECT) combines the administration of bleomycin with temporary permeabilization induced by locally administered electric pulses. Preliminary experience with ECT in BC patients is encouraging. A total of 125 patients with BC skin metastases who underwent ECT between 2010 and 2013 were enrolled onto a multicenter retrospective cohort study. The treatment was administered following the European Standard Operative Procedures of Electrochemotherapy. Tumor response was clinically assessed adapting the Response Evaluation Criteria in Solid Tumors, and toxicity was evaluated according to Common Terminology Criteria for Adverse Events 4.0. Cox regression analysis was used to identify predictive factors. Response was evaluable in 113 patients for 214 tumors (median 1 per patient, range 1-3). The overall response rate after 2 months was 90.2 %, while the complete response (CR) rate was 58.4 %. In multivariate analysis, small tumor size (P < 0.001), absence of visceral metastases (P = 0.001), estrogen receptor positivity (P = 0.016), and low Ki-67 index (P = 0.024) were significantly associated with CR. In the first 48 h, 10.4 % of patients reported severe skin pain. Dermatologic toxicity included grade 3 skin ulceration (8.0 %) and grade 2 skin hyperpigmentation (8.8 %). Tumor 1-year local progression-free survival was 86.2 % (95 % confidence interval 79.3-93.8) and 96.4 % (95 % confidence interval 91.6-100) in the subgroup of those with CR. In this study, small tumor size, absence of visceral metastases, estrogen receptor positivity, and low Ki-67 index were predictors of CR after ECT. Patients who experienced CR had durable local control. ECT represents a valuable skin-directed therapy for selected patients with BC.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 25%
Unspecified 4 14%
Student > Bachelor 4 14%
Researcher 4 14%
Professor 3 11%
Other 6 21%
Readers by discipline Count As %
Medicine and Dentistry 11 39%
Veterinary Science and Veterinary Medicine 4 14%
Unspecified 4 14%
Agricultural and Biological Sciences 3 11%
Engineering 2 7%
Other 4 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2017.
All research outputs
#7,167,730
of 12,419,165 outputs
Outputs from Annals of Surgical Oncology
#1,718
of 2,896 outputs
Outputs of similar age
#105,826
of 235,943 outputs
Outputs of similar age from Annals of Surgical Oncology
#45
of 127 outputs
Altmetric has tracked 12,419,165 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,896 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,943 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 127 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.